ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

Results of the phase III ESPAC-4 trial found that resected pancreatic cancer patients treated with the gemcitabine plus capecitabine had a better estimated 5-year survival rate compared with those treated with gemcitabine alone.

The data (abstract LBA4006) were presented by John P. Neoptolemos, MA, MB, BChir, MD, of the University of Liverpool in the United Kingdom, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. In this video Dr. Neoptolemos discusses the results of the trial as well as the next steps in pancreatic cancer research.

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening

Russ Conroy
September 6th 2025
Article

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC

Roman Fabbricatore
September 2nd 2025
Article

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.

Dendritic Cell Vaccine Shows Preliminary Activity in Advanced HCC

Roman Fabbricatore
August 29th 2025
Article

The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.

Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.

Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer

Russ Conroy
August 27th 2025
Article

Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.